Skip to content
‹ Back to IndustriesSciences

How Basic Chemicals are Being Impacted in the Supply Chain

Key Points: Supply Chain Issues are causing disruptions to the chemical industry. Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions. The big players figured out how to deal with disruptions in the supply chain. Commentary: Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Basic ChemicalsChemical Supply ChainPrice SurgePvc
Share

Key takeaways

01

Key Points: Supply Chain Issues are causing disruptions to the chemical industry.

02

Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.

03

The big players figured out how to deal with disruptions in the supply chain.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Key Points:

  • Supply Chain Issues are causing disruptions to the chemical industry.
  • Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.
  • The big players figured out how to deal with disruptions in the supply chain.

Commentary:

Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as ethylene, PVC, and epoxy resins, are seeing price surges due to these disruptions. We asked Jimmy Jett, CEO of Integrity BioChem, about these demand increases and what sort of role does it play in the overall chemical supply chain issue.

Abridged Thoughts:

Obviously, demand. There is a lot of pent-up demand from the pandemic, as people start to consume more and get back on the roads and travel. You’re seeing a lot of demand. It is unfortunate that demand is spiking, as supply is dwindling. What you’re seeing is that the big players have more sophisticated supply chain systems and have gotten out ahead of it. Some great examples are you’ve seen some of the bigger companies that have even contracted their own fleet to move goods and services around the world. You’re seeing some of the larger players with a really solid plan to mitigate some of the supply chain issues, but the Tier Two and Three companies might not have the cash flow to go out and purchase six months worth of inventory. 

What Can the Pharma Industry Learn from Merck’s New Antiviral?

Will Consumers Be Seeing Higher Prices as the Result of the Tightened Supply Chain?

Video TranscriptExpand ↓

Disruptions in the supply chain are causing problems across every industry. Basic chemicals such as ethylene, PVC and epoxy resins are seeing price surges due to these disruptions. With that in mind, we asked Jimmy, CEO of integrity biochim. About this increases in the man and what sort of role does it play in the overall chemical supply chain issue? You know, obviously demand there's a lot of pent up demand from the pandemic as people start to consume more and get back on the roads and travel. You're seeing a lot of demand, and it's unfortunate that demand is spiking as supply is dwindling. So what you're seeing is the big players that have a more sophisticated supply chain system have gotten out ahead of it. Some great examples or you've seen a lot of the bigger companies that have even contracted their own fleet to move goods and services around the world. And so you're seeing some of the larger players with a really solid plan to mitigate a lot of the supply chain issues. But the tier two and tier three companies that might not have the cash flow to go out and purchase six months worth of inventory are feeling it the most and you're going to see. And then the reality is in the US that tier two and tier three support system in manufacturing than in the chemical space that goods and services, it makes up a massive percentage of the market. So you're going to see a very compressed manufacturing base that are able to get the products. And so with that are going to come a lot of delays. You can just expect, you know, lead times to go from 2 to three weeks to six months and even pushed out further. So it's going to be interesting as the market tries to correct. We already know what these issues are doing to chemicals such as ethylene, PVC and epoxy resins. But what about the sustainable, bio based chemicals? Are they being impacted similarly or in a completely different way? So the sustainable supply chain, you know, the surfactants or the based surfactants and the chemical side have not been impacted. But what you're going to find is that a lot of the technology out there, you obviously don't have the production capacity that is built into their traditional synthetic market. So a lot of the fermentation capacity has come a long way and you're going to see them surge over the next six months because they're going to be able to produce what they can. However, what they can produce is just a fraction of what the industry needs. A lot of the vegetative sources like integrity biochem uses, they're going to be more readily available as well, but they're emerging technologies and they might not have the adoption that traditional synthetics have. So it's going to be interesting to see how quickly you can get these chemistries into the supply chain and through the regulatory side in an expedited way to make an impact. Finding solutions to these supply chain issues is something every industry is trying to figure out when it comes to chemical producers. What strategies should they implement westjet? Should they be investing in New supply chain partnerships, new chemical compounds or new production workflows? And this is what he had to say. I think it's definitely a mix. I mean, you have to be looking at alternative supply partners immediately to secure the pent up demand that is required to run your business. But, you know, in a congruent path, you need to be also looking at New technologies that might supplement or even replace some of these existing technologies. You know, one of the things I love about this industry is that innovation is born in difficult supply markets. When there's challenges out there, a lot of new stuff is developed and a lot of new markets are created. So I'm excited to see what happens. I mean, America is we are excellent at adapting. And so I think we're going to see a lot of neat new technologies emerge and a lot of sustainable products that might have been on the sidelines are going to have a shot to come in and replace some of the sympathetics that you just can't get right now. Chemical energy and its demands is something that needs to be closely evaluated, especially when it's in high demand and a supply chain process is facing as many issues as it is. For more stories of energy and its supply chain effects, be sure to head to Marcus gmail.com as well as subscribe.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Photonic AI hardware is now in outside testers' hands

Photonic AI hardware is now in outside testers' hands

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and expansions like Kopin's could draw from that same pool.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant and expects its first building to open in 2030

Eli Lilly held a groundbreaking on Oct. 22 for a $5 billion manufacturing plant in Goochland County, Virginia. The company expects the first building to open in 2030. Lilly has also committed $40 million to the Virginia Center for Advanced Pharmaceutical Manufacturing, a statewide workforce development network that brings together industry, government and higher education partners. The network's plans include a pilot-scale training center in Goochland County, slated to open in 2028. That timing could let workers start training before the plant begins production.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Celliaz is betting on one AAV2 vector for an eye disease with 90-plus gene causes

Andelyn Biosciences will develop and manufacture CLZ002, Celliaz’s investigational AAV2 gene therapy for retinitis pigmentosa, supporting IND-enabling studies and a planned Phase 1/2 trial. CLZ002 targets a retinal repair mechanism rather than specific mutations. If it works as intended, one manufacturing process could serve patients across many genetic causes of the disease.

  • 01Retinitis pigmentosa can arise from mutations in more than 90 genes; CLZ002 targets a retinal repair mechanism, and if it works as intended one AAV2 manufacturing process could serve patients that gene-specific programs would split into many products.
  • 02For a pre-IND sponsor, putting plasmid and viral vector production with one CDMO can mean fewer handoffs, and the questions worth settling early are who owns the process built on a proprietary platform and how it would move if needed.

Nov 14, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512